Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Coverage Criteria vs. Clinical Reality: Navigating Medicaid Barriers to Tirzepatide Access
Journal of health care for the poor and underserved;37(4):1446-1450
PET Imaging of Dual GLP-1R and GIPR Targeting with [18F]AlF-NOTA-Asp2-Tirzepatide
Molecular pharmaceutics;23(11):5620-5629
Tirzepatide-associated severe euvolemic hyponatremia with syndrome of inappropriate antidiuretic hormone secretion-compatible biochemical features
Indian journal of pharmacology, 2026;58(6):798-800
GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study
Balkan medical journal, 2026
Semaglutide and Cardiovascular Death: a Systematic Review and Meta-Analysis Cardioprotective Efficacy of Semaglutide
Critical pathways in cardiology, 2026
The pharmacological frontier in obstructive sleep apnoea: From pathophysiologic endotypes to precision medicine
Lung India : official organ of Indian Chest Society, 2026;43(6):718-725
Baseline monocyte GIP receptor mRNA expression is associated with reductions in body weight and FIB-4 index after switching to tirzepatide in patients with type 2 diabetes
Diabetology international, 2026;18(1):4
Efficacy and safety of semaglutide versus placebo in adults with overweight or obesity without diabetes: updated meta-analysis of randomized trials
Journal of diabetes and metabolic disorders, 2026;25(2):305
Analysis Asks: Are GLP-1 Drugs Safe in People With Frailty?
JAMA, 2026
Glucagon-Like Peptide-1 Analog-Type Amyloidosis: A Case Report and Review of the Literature
The American Journal of dermatopathology, 2026
Combined time-restricted feeding and resistance training enhance tirzepatide-induced improvements in adiposity and whole-body insulin sensitivity in female mice
The Journal of physiology, 2026
Activities of daily living and health status benefits of semaglutide in very old patients with heart failure, type 2 diabetes, and obesity: Real-world practice study
Medicina clinica, 2026;:107663
The metabolic-brain axis: GLP-1 signaling, insulin resistance, and obesity pharmacotherapy in neurodegeneration
Metabolism: clinical and experimental, 2026;:156810
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
The lancet. Diabetes & endocrinology, 2026
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns
JACC. Advances, 2026;5(12 Pt 2):103402
Comparative Effects of Pharmacological Treatment on Heart Failure with Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials
Drugs, 2026
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
Endocrine, 2026;91(1)
Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
Expert opinion on pharmacotherapy, 2026
Cutaneous vasculitis associated with subcutaneous semaglutide
Endocrinologia, diabetes y nutricion, 2026;:501828
Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study
Diabetes, obesity & metabolism, 2026